IL2 and neoplasm: Recently, we and others have demonstrated that combination therapy (CT) with co-administration of IL-2 and TGF-β neutralization in tumor-bearing mice results in the expansion of NK and CD8 T cells and consequently enhanced anti-tumor responses [27,28].